Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 70% Improvement Relative Risk Hospitalization 35% HCQ for COVID-19  Mokhtari et al.  EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Retrospective 28,759 patients in Iran Lower mortality (p<0.0001) and hospitalization (p<0.0001) Mokhtari et al., Int. Immunopharmacology, Apr 2021 Favors HCQ Favors control

Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting

Mokhtari et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107636
Apr 2021  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective 28,759 adult outpatients with mild COVID-19 in Iran, 7,295 treated with HCQ, showing significantly lower hospitalization and mortality with treatment.
risk of death, 69.7% lower, RR 0.30, p < 0.001, treatment 27 of 7,295 (0.4%), control 287 of 21,464 (1.3%), NNT 103, adjusted per study, odds ratio converted to relative risk.
risk of hospitalization, 35.3% lower, RR 0.65, p < 0.001, treatment 523 of 7,295 (7.2%), control 2,382 of 21,464 (11.1%), NNT 25, adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mokhtari et al., 6 Apr 2021, retrospective, Iran, peer-reviewed, 12 authors, dosage 400mg bid day 1, 200mg bid days 2-5.
This PaperHCQAll
Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting
Majid Mokhtari, Minoo Mohraz, Mohammad Mehdi Gouya, Hengameh Namdari Tabar, Jafar-Sadegh Tabrizi, Katayoun Tayeri, Saeide Aghamohamadi, Zahra Rajabpoor, Manoochehr Karami, Alireza Raeisi, Hamid Rahmani, Hossein Khalili
International Immunopharmacology, doi:10.1016/j.intimp.2021.107636
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Bessière, Roccia, Delinière, Charrière, Chevalier et al., Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit, JAMA Cardiol, doi:10.1001/jamacardio.2020.1787
Bhimraj, Morgan, Shumaker, Lavergne, Baden, Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19, Clin. Infect. Dis, doi:10.1093/cid/ciaa478
Clancy, Nguyen, A first draft of the history of treating coronavirus disease 2019 (COVID-19): Use of repurposed medications in United States hospitals, Open Forum Infect. Dis, doi:10.1093/ofid/ofaa617
Derwand, Scholz, Zelenko, COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.106214
Duvignaud, Lhomme, Pistone, Onaisi, Sitta et al., Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial), Trials, doi:10.1186/s13063-020-04619-1
Fonseca, De Queiroz, Sousa, Wolkoff, Moreira et al., Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis, Travel Med. Infect. Dis
Gandhi, Lynch, Del Rio, Mild or Moderate Covid-19, N. Engl. J. Med, doi:10.1056/NEJMcp2009249
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.105949
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2012410
Ghaffari Darab, Keshavarz, Sadeghi, Shahmohamadi, Kavosi, The economic burden of coronavirus disease 2019 (COVID-19): evidence from Iran, BMC Health Serv Res, doi:10.1186/s12913-021-06126-8
Göpel, Bethge, Martus, Kreth, Iftner et al., Test and treat COVID 65 plus -Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial, Trials, doi:10.1186/s13063-020-04556-z
Heart, Lung, Blood, Network, Steingrub et al., Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2020.22240
Ip, Ahn, Zhou, Goy, Hansen et al., Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study, medRxiv preprints, doi:10.1101/2020.08.20.20178772
Jalili, Payandemehr, Saghaei, Sari, Safikhani et al., Characteristics and Mortality of Hospitalized Patients With COVID-19 in Iran: A National Retrospective Cohort Study, Ann. Intern. Med, doi:10.7326/M20-2911
Lagier, Million, Gautret, Colson, Cortaredona et al., 19 Task force. Outcomes of 3737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101791
Lofgren, Nicol, Bangdiwala, Pastick, Okafor et al., Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. Open Forum, Infect Dis, doi:10.1093/ofid/ofaa500
Mercuro, Yen, Shim, Maher, Mccoy et al., Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19), JAMA Cardiol, doi:10.1001/jamacardio.2020.1834
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101738
Mitjà, Corbacho-Monné, Ubals, Tebe, Peñafiel et al., Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial, Clin Infect Dis, doi:10.1093/cid/ciaa1009
Mohana, Sulaiman, Mahmoud, Hassanein, Alfaifi et al., Hydroxychloroquine safety outcome with an approved therapeutic protocol for COVID-19 outpatients in Saudi Arabia, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.10.031
Pan, Peto, Henao-Restrepo, Preziosi, Sathiyamoorthy et al., Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results, N Engl. J. Med, doi:10.1056/NEJMoa2023184
Prodromos, Rumschlag, Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review, New Microbes New Infect, doi:10.1016/j.nmni.2020.100776
Raeisi, Tabrizi, Gouya, IR of Iran National Mobilization against COVID-19 Epidemic, Arch Iran Med, doi:10.34172/aim.2020.01
Recovery Collaborative Group, Horby, Mafham, Linsell, Bell et al., Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl. J. Med, doi:10.1056/NEJMoa2022926
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment with Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State, JAMA, doi:10.1001/jama.2020.8630
Self, Semler, Leither, Casey, Angus et al., None
Skipper, Pastick, Engen, Bangdiwala, Abassi et al., Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial, Ann. Intern. Med, doi:10.7326/M20-4207
Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis, doi:10.1093/cid/ciaa237
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop